Loading provider…
Loading provider…
Hematology & Oncology Physician in New Orleans, LA
NPI: 1407146418Primary Practice Location
OCHSNER MEDICAL CENTER ACUTE
1221 S Clearview Pkwy, New Orleans, LA
Primary Employer
Ochsner Clinic LLC
ochsner.org
HQ Phone
Get MD Carter's Phone Numberphone_androidMobile
Get MD Carter's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardLA State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 105 | 170 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 86 | 253 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 35 | 44 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 31 | 118 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 19 | 20 |
Immunotherapeutic applications of NK cells.
Authors: Davis, Carter T, Rizzieri, David
Journal: Pharmaceuticals (Basel)
Publication Date: 2015-05-25
A role for the androgen receptor in the treatment of male breast cancer.
Authors: Jason Zhu, Carter Davis, Sandra Silberman, Neil Spector, Tian Zhang
Publication Date: 2015-04-10
Clinical case of the month. A 48-year-old man with right lower extremity weakness and pain.
Authors: Kian Ehsan, Frederick Helmcke, Jeffrey Melancon
Journal: J La State Med Soc
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Bone Marrow Biopsy, DRUG: Venetoclax, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Ibrutinib, PROCEDURE: Computed Tomography, BIOLOGICAL: Obinutuzumab
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Venetoclax, DRUG: Ibrutinib, BIOLOGICAL: Obinutuzumab, OTHER: Observation Activity
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: BIOLOGICAL: Nivolumab, OTHER: Laboratory Biomarker Analysis, DRUG: Azacitidine, DRUG: Decitabine, DRUG: Midostaurin, DRUG: Cytarabine